Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme

Jiemiao Hu(The University of Texas MD Anderson Cancer Center), Qingnan Zhao(The University of Texas MD Anderson Cancer Center), Ling-Yuan Kong(The University of Texas MD Anderson Cancer Center), Jian Wang(The University of Texas MD Anderson Cancer Center), Jun Yan(The University of Texas MD Anderson Cancer Center), Xueqing Xia(The University of Texas MD Anderson Cancer Center), Zhiliang Jia(The University of Texas MD Anderson Cancer Center), Amy B. Heimberger(The University of Texas MD Anderson Cancer Center), Shulin Li(The University of Texas MD Anderson Cancer Center)
Science Advances
January 27, 2021
10.1126/sciadv.abc2511
Cited by 141Open Access
Full Text

Abstract

T cell accumulation in vitro and in vivo. CXCL1/2 also promoted the paracrine factor S100A9 and further activated Erk1/2 and p70S60k, whereas blocking CXCL1/2 down-regulated these prosurvival factors. The combination of targeting CXCL1/2 and standard temozolomide chemotherapy improved upon the antitumor efficacy of chemotherapy alone, extending the overall survival time in GBM.

Related Papers

No related papers found

Powered by citation graph analysis